Peter Greenleaf

Peter Greenleaf

Ordförande på
Maryland Venture Fund

Förmögenhet: 28 M $ per 2026-07-31

56 år
Health Technology
Finance
Commercial Services

Profil

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Kända innehav i offentliga företag

FöretagDatumAntal aktierVärderingVärderingsdatum
2026-03-02 1 840 379 ( 1,43 % ) 27 M $ 2026-07-31
0,69 %
2026-07-02 23 884 ( 0,69 % ) 684 515 $ 2026-07-31

Senaste nyheterna om Peter Greenleaf

Aktiva positioner av Peter Greenleaf

FöretagPositionStart
Ordförande -
Ordförande 2020-12-17
Konsult / Rådgivare -

Tidigare kända positioner av Peter Greenleaf

FöretagPositionSlut
AURINIA PHARMACEUTICALS INC. Verkställande Direktör 2026-03-23
ANTARES PHARMA, INC. Direktör/Styrelseledamot 2022-05-24
BIODELIVERY SCIENCES INTERNATIONAL, INC. Ordförande 2022-03-22
AVALO THERAPEUTICS, INC. Verkställande Direktör 2019-04-15
KIORA PHARMACEUTICALS, INC. Direktör/Styrelseledamot 2020-01-03
Se detaljerna i Peter Greenleafs erfarenhet

Peter Greenleafs utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

74

Första gradens relationer

33

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Börsen
  2. Insiders
  3. Peter Greenleaf